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Abstract
In vivo 31P MRS demonstrates that human melanoma xenografts in immunosuppressed mice
treated with lonidamine (LND, 100 mg/kg, i.p.) exhibit a decrease in intracellular pH (pHi) from
6.90 ± 0.05 to 6.33 ± 0.10 (p < 0.001), a slight decrease in extracellular pH (pHe) from 7.00 ± 0.04
to 6.80 ± 0.07 (p > 0.05), and a monotonic decline in bioenergetics (NTP/Pi) by 66.8 ± 5.7% (p <
0.001) relative to the baseline level. Both bioenergetics and pHi decreases were sustained for at
least 3 hr following LND treatment. Liver exhibited a transient intracellular acidification by 0.2 ±
0.1 pH units (p > 0.05) at 20 min post-LND with no significant change in pHe and a small
transient decrease in bioenergetics, 32.9 ± 10.6 % (p > 0.05), at 40 min post-LND. No changes in
pHi or ATP/Pi were detected in the brain (pHi, bioenergetics; p > 0.1) or skeletal muscle (pHi,
pHe, bioenergetics; p > 0.1) for at least 120 min post-LND. Steady-state tumor lactate monitored
by 1H MRS with a selective multiquantum pulse sequence with Hadamard localization increased
~3-fold (p = 0.009). Treatment with LND increased systemic melanoma response to melphalan
(LPAM; 7.5 mg/kg, i.v.) producing a growth delay of 19.9 ± 2.0 d (tumor doubling time = 6.15 ±
0.31d, log10 cell-kill = 0.975 ± 0.110, cell-kill = 89.4 ± 2.2%) compared to LND alone of 1.1 ±
0.1 d and LPAM alone of 4.0 ± 0.0 d. The study demonstrates that the effects of LND on tumor
pHi and bioenergetics may sensitize melanoma to pH-dependent therapeutics such as
chemotherapy with alkylating agents or hyperthermia.
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Introduction
Melanoma, the deadliest skin cancer (1) is the most rapidly increasing form of human cancer
among Caucasian populations in the world (2). Presently, melanoma is primarily treated by
surgical excision, which is often curative if the tumor is detected in its early stages.
However, if recurrence occurs with metastasis, the prognosis is very poor since effective
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methods for treating systemic disease are not available. Limited success has been achieved
with agents that target the V600D, E, K, BRAF mutation observed in about 50% of
melanomas (3, 4) and with Ipilumimab (5, 6) but none of these have been curative. The most
promising approach for systemic treatment of this disease will probably be the development
of multiple therapeutic agents functioning by a variety of independent mechanisms that
would be very difficult to simultaneously circumvent. The present study demonstrates one
such method that utilizes the Warburg effect and agents that trap lactate in tumors to
selectively acidify melanoma and sensitize it to systemic therapy with conventional
alkylating agents.
Intracellular acidification has been reported to potentiate tumor response to hyperthermia
(7–9) as well as to chemotherapy with platinum (10) and N-mustard (11–13) alkylating
agents. In preliminary studies of mice bearing subcutaneously implanted human DB-1
melanoma xenografts, we have achieved about 40 minutes of selective acidification of these
tumors to a pHi of 6.2± 0.2 by administering high levels of exogenous glucose together with
an inhibitor of oxidative phosphorylation, meta-iodobenzylguanidine (MIBG) and an
inhibitor of the monocarboxylic acid transporter (MCT) (14)α-cyano-4-hydroxycinnamate
(CHC) to block export of lactic acid from the tumor cells (15). Tumor acidification was
accompanied by a decrease in the bioenergetic status of the tumor (NTP/Pi) by about 50%.
A similar procedure was also conducted on a nude rat model of human melanoma xenografts
that were treated with melphalan (LPAM) during isolated limb perfusion; local acidification
was induced by administering glucose by intravenous infusion (26 mM) plus MIBG (22.5
mg/kg); subsequent infusion of LPAM produced a 51 day growth delay, whereas LPAM
administered without glucose and MIBG produced only a 21 day growth delay (16).
These preliminary results could not be translated into the clinic, however, because CHC is
not FDA approved, and MIBG is only approved for human use at tracer concentrations
suitable for treatment with the radio-iodinated drug. Therefore, we performed studies with
the putative MCT inhibitor lonidamine (LND), which has been widely used in Europe and
Canada. This agent acidified the tumor under hyperglycemic conditions (26 mM blood
glucose) for over 3 hr and also dramatically decreased NTP/Pi, but the animals died after the
experiments were completed.
The goals of the present study were to set the stage for clinical translation by developing a
treatment procedure that is reproducibly effective and produces selective acute acidification
of the DB-1 melanoma with minimal toxicity to the host. There is also continuing
controversy over the mechanism of action of LND that we sought to resolve. Finally, since
acute acidification has been reported to enhance the activity of platinum compounds (10)
and alkylating agents such as nitrogen (N)-mustards (10–13, 16–19), we have evaluated the
effect of LND-induced acidification on one representative agent, LPAM. We found that
while LND alone had no significant effect on tumor growth delay, it substantially enhanced
the activity of LPAM and did not substantially increase the toxicity of this antineoplastic
agent. These findings point to the potential utility of nitrogen mustards and LND in the
systemic treatment of disseminated melanoma.
Materials and Methods
Subjects
Fifteen tumor-bearing mice were included in the study. Of the 15 tumors studied, 7 were
evaluated by nonlocalized and 8 by localized 31P MRS. Mice without tumors were
employed in studies of normal tissues, brain pHi (n = 3), surgically exposed liver pHi (n =
6), pHe (n = 3) and skeletal muscle pHi (n = 6), pHe (n = 3), under identical conditions
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utilized for 31P MRS studies of mice with tumors. Three tumor-bearing mice were included
for lactate measurement experiments following LND administration.
Materials
LND and 3-aminopropylphosphonate (3-APP) were purchased from Santa Cruz Bio-
technology, Inc (Santa Cruz, CA, USA). The drug (LND; 5 mg) was dissolved in 227 μL of
tris/glycine buffer (22.0 mg/mL), vortexed until the solution was clear and administered i.p.
(intraperitoneal) at a dose of 100 mg/kg. The buffer consisted of trizma base (1.2 g) and
glycine (5.76 g) in 100 mL sterile water (final pH = 8.3). In addition, 0.2 ml of a 300 mg/ml
solution of 3-APP (dissolved in water and pH adjusted to 7) was administered i.p. LPAM
was purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA) and was
dissolved by solubilization in 5% acid (HCl)/ethanol at 15 mg/ml followed by 10-fold
dilution with PBS (1.5 mg/ml) immediately prior to i.v. administration (7.5 mg/kg).
Human Melanoma Xenografts in Nude Mice
Male athymic nude mice (01B74) 4–6 weeks of age obtained from the National Cancer
Institute, Frederick, MD, USA were housed in microisolator cages and had access to water
and autoclaved mouse chow ad libitum. DB-1 melanoma cells were obtained and preserved
as discussed before (14). Cells expressed human melanoma antigens (20). DB-1 cells were
grown as monolayers at 37°C in 5% CO2 in α-MEM (Invitrogen/Gibco, Carlsbad, CA,
USA) supplemented with 10% fetal calf serum, 1% glutamine, HEPES, penicillin,
streptomycin and glucose (2.5 M). One million melanoma cells in 0.10 mL of Hank’s
balanced salt solution (Invitrogen/Gibco, Carlsbad, CA, USA) were inoculated
subcutaneously into the right thigh of each animal. Melanoma xenografts were allowed to
grow until the tumor volume reached ~300 mm3 before further study. The tumor dimensions
were measured with calipers in three orthogonal directions, and the volume was calculated
using the equation, V= π(a×b×c)/6, where a, b, and c are the length, width, and depth of the
tumor.
Animal Preparation
For induction of anesthesia, tumor-bearing mice were administered an i.p. cocktail
containing ketamine hydrochloride (10 mg/mL) and acepromazine (1 mg/mL) with the total
dose equivalent to 50 mg/kg ketamine and 5 mg/kg. Once positioned for study, animals were
maintained under 1% isoflurane in oxygen, supplied at 1 L/min. Changes in pHi and pHe in
response to LND were monitored in tumor, brain, skeletal muscle, and exposed liver of nude
mice. Tumor, skeletal muscle (hind-leg) and exposed liver were studied by positioning the
tissue in a home-built dual-frequency (1H/31P) slotted-tube resonator (13 mm in diameter).
Brain 31P MRS was implemented by placing the animal’s head on top of a 20 mm 31P
surface coil in conjunction with a 70 mm quadrature 1H volume coil (T/R). For 31P MRS
experiments on liver, a 1-cm incision was made in the abdomen of the anesthetized animal
to expose the liver, and the exposed organ was placed inside the resonator. During the liver
studies some surface dehydration was evident in the surgically exposed liver; this produced
some discoloration of the liver surface and small modifications of the 31P spectrum. Both
effects of dehydration were eliminated by placement of a parafilm insert filled with saline
inside the resonator to maintain hydration of the tissue. For lactate measurements following
LND administration, tumors were positioned in a home-built single frequency (1H) slotted
tube resonator (inner diameter = 13 mm, outer diameter = 15 mm, depth = 16.5 mm).
MR Experiment and pH Estimation
MR experiments were performed on a 9.4 T/31 cm horizontal bore Varian system. In
vivo 31P MR spectra were acquired with a homemade resonator as described above. Sub-
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dermal needle electrodes and a rectal thermistor were placed for electrocardiogram and core
body temperature monitoring, respectively. The animal’s core body temperature was
maintained at 37 ± 1°C by blowing warmed air into the bore of the magnet during a scan
with heating controlled by a thermal regulator system. A respiration pillow was placed over
the thorax and a pulse-oximeter over the tail to monitor respiration and oxygen saturation,
respectively (Model 1025, SA Instruments Inc., Stony Brook, NY, USA). For measurement
of pHe (21), LND and 3-APP were injected following acquisition of the baseline spectrum
through two 26 gauge i.p. catheters inserted into either side of the peritoneum without
removing the animal from the magnet. The magnet was shimmed until the water line-width
of the tumor monitored via the 1H channel reached 60–70 Hz. Nonlocalized 31P MRS
experiments were performed using the following parameters: 128 scans (NT) with an rf
pulse width of 60 μs, corresponding approximately to a 90° flip angle; 12 kHz sweep width
(SW); 512 data points (NP); TR of 4 sec. Localized 31P MRS was performed on tumor (n=8)
and brain (n=3) using the ISIS (Image Selected In vivo Spectroscopy) technique with the
following parameters: NT = 256 with an rf pulse width of 60 μs, corresponding
approximately to a 90° flip angle; SW =12 kHz; NP = 512; TR of 4 sec. In order to permit
simultaneous measurement of pHi, pHe and NTP/Pi ratios in single 31P MRS spectra, we
chose to use the pHe indicator 3-APP rather than a 1H detectable probe (22), which could
have provided higher spatial resolution. The localization method (ISIS) requires calibration
of pulse parameters that is very demanding and time consuming. When we did, we found
that the results obtained with ISIS localization were consistent with the nonlocalized spectra.
A PRESS (Point Resolved Spectroscopy) sequence was used to shim the ISIS tumor voxel,
as well as the voxel localized studies of the brain. A slice selective double frequency
Hadamard Selective Multiple Quantum Coherence (Had-Sel-MQC) pulse sequence was
used to detect lactate and to filter out overlapping lipid signals (23). The acquisition
parameters were: SW = 4 kHz, NP = 2048, TR = 8 s, NT = 128. NUTS (Acorn NMR Inc.,
Livermore, CA, USA) and MestRec (Mestrelab Research, Santiago de Compostela, Spain)
were used to process all spectroscopic data. A 20 Hz exponential filter was used to improve
the apparent signal-to-noise ratio of 31P MRS data, and base-line correction was applied
before plotting and calculating peak areas. The pHi was determined from the chemical shifts
of Pi referenced to the α-NTP resonance.
Intracellular and extracellular pH was determined as discussed before (14). For pHe, the pKa
of 6.90 ± 0.03, limiting acid chemical shift of 34.22 ± 0.04 ppm, and base chemical shift of
31.08 ± 0.04 ppm were used, and for pHi, the corresponding parameters were 6.57 ± 0.03,
13.52 ± 0.03, and 11.24 ± 0.02 ppm, respectively (14, 24–26). For each animal, the change
in NTP/Pi (bioenergetics status) relative to its baseline value was determined after LND
administration.
Treatment with Chemotherapy and Tumor Volume Measurement
When tumors reached ~250 mm3 in volume, four cohorts of five age- and weight-matched
animals were randomized to the following treatment groups: cohort 1 (sham treated control)
was infused intravenously (i.v.) with PBS and given appropriate sham intraperitoneal (i.p.)
injections of tris/glycine buffer; cohort 2 was infused i.v. with PBS 40 minutes after LND
administration i.p. (100 mg/kg); cohort 3 was injected i.p. with tris/glycine buffer and
infused i.v. with LPAM (7.5 mg/kg delivered in ~10 sec) in PBS; cohort 4 was injected i.p.
with LND (100 mg/kg) and after 40 minutes, LPAM (7.5 mg/kg) was infused i.v.
During the treatment and sham-treatment procedures, all animals were anesthetized with
ketamine hydrochloride and acepromazine as described above with additional anesthesia
being readministered as needed approximately every 45–60 min. Animals were placed on a
water pad heater (Gaymar T-Pump) to maintain body temperature during anesthesia. Tumor
dimensions were measured as well as animal body weight. Tail vein catheters (I.V.
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Catheters FEP, Tyco Healthcare) filled with heparin (100 USP Units/mL) to prevent blood
clotting were placed using a restrainer (MTI Braintree Scientific). LPAM was freshly
prepared prior to injection. Depending on the treatment group, either tris/glycine or LND
(4.5 ul/g) and LPAM or PBS (5.0 ul/g) were injected. Tail vein catheters were removed and
animals were allowed to recover in cages.
For the first five days post-treatment, tumor volume and body weight were measured daily
with calipers (Scienceware) and scale (Acculab PP-401), respectively. Afterwards, these
measurements were repeated every other day.
Statistics
ANOVA with Bonferroni and Tukey multiple comparisons were used for statistical analysis
(STATA® software version 12.0). The data of pHi, pHe, lactate, NTP/Pi at time points
following LND administration were compared. We tested the null hypothesis versus
alternative hypothesis at the significance level of α = 0.05. To assess the significance of
treatment effects, we fit spline models to the longitudinal tumor growth data (27). The
models described log tumor volume as linear throughout the period of observation in the
control arm and prior to treatment in the active arms, and as a quadratic spline in the period
immediately after treatment in the active arms. We evaluated significance of the treatment
effects by likelihood ratio tests involving the spline coefficients. We conducted the tumor
growth modeling in SAS Proc Mixed (SAS Version 9.2; SAS Institute; Cary, NC). Other
analyses were performed in Microsoft Excel 2010.
Results
A representative localized 31P MR spectrum of human melanoma xenografts prior to
administration of LND is shown in figure 1A. The corresponding spectrum following
injection of LND is shown in figure 1B.
The pHi and pHe profiles of the melanoma xenografts after LND administration are plotted
in figure 2A, B, respectively. The MR experiments showed a monotonic decrease in tumor
pHi after LND administration (Fig. 2A). A maximum decrease in tumor pHi of 0.6 ± 0.1
units (p < 0.001) was observed at 80 min following LND administration. However, the
tumor pHe exhibited a smaller gradual decline by 0.2 ± 0.07 units overall (p > 0.05) (Fig.
2B). The pHi and pHe changes in normal tissues (liver, skeletal muscle, and brain) in
response to LND administration are summarized in figure 2A, B, respectively. The
surgically exposed liver showed a small transient decrease in pHi of 0.2 ± 0.1 units (p >
0.05) 20 min post-administration of LND and then returned to pretreatment pHi values.
Skeletal muscle (p > 0.05) and brain (p = 0.953) exhibited no significant change in pHi. We
also didn’t observe a significant change in pHe of skeletal muscle (p = 0.312) or liver (p =
0.345) after LND administration, whereas the pHe of brain could not be measured because
3-APP did not cross the blood brain barrier. The bioenergetics of melanoma xenografts and
normal tissues were determined from the respective changes in NTP/Pi relative to their
baseline levels (Fig. 2D). Evanochko et al. previously reported that the nucleoside
triphosphate signal from tumors originates from a mixture of all four nucleotide bases (28),
whereas in normal tissues ATP is the predominant nucleotide. As such, values from tumor
are represented as NTP and those from brain, liver and muscle are presented as ATP. In
tumors the NTP/Pi remained low at 66.8 ± 5.7% (p < 0.001) of the baseline level for up to
180 min. However, there was a great range of variability in these 15 measurements (ranging
from 6.14 to 77.72%) that went into determining the average change in this ratio. We
observed a transient decrease in the liver NTP/Pi while monitoring from baseline (t = 0)
until t = 120 min with a maximum decrease of 32.9 ± 10.6% from the baseline ratio (p >
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0.05) at t = 40 min. There was no significant change in the bioenergetics of brain (p > 0.05)
or skeletal muscle (p > 0.05).
Steady-state levels of tumor lactate (intracellular plus extracellular) were monitored by 1H
MRS with the Had-Sel-MQC pulse sequence. Figure 3 shows representative spectra from
one of the three animals that were observed. The integrated intensities of the steady-state
lactate peaks relative to the baseline level (as 1.0) were 1.89, 2.27, 3.03, 2.45, 2.30, 2.20,
1.92, 1.79 and 1.52. A U (arbitrary unit) following LND administration at 20, 40, 60, 80,
100, 120, 140, 160 and 180 min, respectively. Lactate intensity peaked at 60 min post LND
administration was greater than baseline (p = 0.009) integrated intensity and then decreased
monotonically (Fig. 2C), (Fig. 3). Note that the decrease in pHi was 0.6 ± 0.1 units, whereas
the decrease in pHe was 0.2 ± 0.07 units; since the extracellular volume fraction ranges
between about 30 and 50% in experimental tumors (29), this indicates that most of the lactic
acid was confined to the intracellular compartment. There was no observed change in tumor
pHi, pHe and bioenergetics over a 3 hr period after administration of 3-APP alone (data not
shown). 31P MRS demonstrates that the administration of LND increased the pH gradient
across the tumor cell membrane: pHe went from 7.00 ± 0.04 to 6.80 ± 0.07 (p > 0.05) while
pHi went from 6.90 ± 0.05 to 6.33 ± 0.10 (p < 0.001).
In preparation for studies combining LND with alkylating agents, we performed ex vivo
studies of the effects of a number of candidate platinum and alkylating agents on cultured
DB-1 melanoma cells. LPAM exhibited the greatest cytotoxicity as a single agent, followed
by cisplatin, bendamustine and chlorambucil. LND also exhibited a low level of cytotoxicity
as a single agent.
The effects of treatment with LND plus LPAM were evaluated by tumor growth delay
experiments (Fig. 4). The effect of treatment with LND + LPAM was significantly different
from placebo, LND alone, and LPAM alone (P < 0.0001 for all three comparisons).
Tumor growth delay was determined by calculating the time in days between logarithmic
regrowth regions of the curves of treated tumors and saline treated controls. Data yielded
tumor growth delays in a representative experiment of 1.1 ± 0.1 d, 6.6 ± 0.0 d and 19.9 ± 2.0
d for LND alone, LPAM alone and LND + LPAM, respectively (Fig. 4). Tumor doubling
times were estimated from the slopes of the log-linear portion of the tumor regrowth curves
determined by linear regression analysis using the formula Td = 0.3010/m, where m is the
slope. The value of log10 cell-kill, 0.975, estimated from the t = 0 intercept of the plot of log
V vs. time, where V = tumor volume, was in excellent agreement with the value obtained
from the formula log10 cell kill = (T-C)/3.32Td = 0.975 ± 0.110 (30). Graphical analysis
then yields the estimated cell-kill as 89.4 ± 2.2% for LND + LPAM.
Effects of treatment on host body weight reflected overall systemic toxicity. LPAM plus
LND, produced a 15.7 ± 3.5% decrease in body weight, but recovery to the control growth
rate was complete by 2 wk. The LPAM plus LND results look very encouraging with full
recovery of body weight in 14 d and a net tumor growth delay of about 20d.
Discussion
Since the seminal description by Warburg’s laboratory that most tumors exhibit high levels
of aerobic glycolysis (31, 32), methods have been explored to utilize the “Warburg Effect”
for the treatment of cancer, particularly using alkylating agents that are sensitized by acid
(10–13) or heat, whose lethal effect is also enhanced under acidic conditions (7–9). Since
the MCT is the main mechanism by which the DB-1 melanoma (33) and most other tumors
(34) maintain pHi homeostasis, inhibition of this co-transporter would suffice to acidify the
tumor.
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Spencer and Lehninger (35) first inhibited transport of lactate and pyruvate by administering
the MCT inhibitor CHC, which prevented transport of both substituted monocarboxylic
acids like lactate and pyruvate but not simple uniacids like acetate or propionate. LND is not
as well-documented as an MCT inhibitor, and there have been claims that it was an inhibitor
of hexokinase-2 and, hence, glycolysis (36, 37). However, figures 2C and 3 clearly
demonstrate that LND increases steady state lactate levels in the tumor by about a factor of
three; this was predominantly in the intracellular compartment since pHi decreased much
more than pHe. This appears to argue against inhibition of glycolytic metabolism, although
other metabolic pathways could also lead to lactic acid production; therefore, quantitative
studies of glycolytic pathways will be required to definitively delineate the source of the
increased intracellular lactate. Mardor et al. (38) elegantly used diffusion-weighted imaging
to demonstrate an increase in intracellular lactate in perfused MCF-7 breast cancer cells
following LND treatment. The decrease in pHi induced by LND with minimal change in
pHe (Fig. 2) points to the same conclusion as did Ben-Horin et al. (39) on the basis of 31P
MRS studies of perfused MCF-7 cells, who also demonstrated by 13C MRS that [2-13C]
lactate formed from [1-13C] glucose was retained in the tumor cells after administration of
LND. 31P MRS studies by Ben-Yoseph et al. (40) of s.c. 9L glioma tumors in rats confirmed
retention of acid under in vivo conditions following treatment with LND. Our studies have
extended these observations by showing that the effects of LND were restricted to the tumor,
by monitoring lactate by 1H MRS in vivo and also by showing that lactic acid is retained for
at least 3 hr (Fig. 2C), (Fig. 3). This provides a much longer time window for administration
of drugs that could be activated by acid than possible with MIBG or CHC alone (~40 min).
These extensions beyond the previous studies are critical to ultimate clinical translation.
While LND must be clearly inhibiting export of lactate from the tumor cells of human
(DB-1 and MCF-7) and rat origin (9L), it is not clear if it is inhibiting transport of pyruvate
into mitochondria as CHC does (35). However, the similar effect of CHC and LND on the
bioenergetics of DB-1 melanomas strongly suggests that it is (15).
Therefore, the decline of bioenergetics that was evident both from the decrease in NTP/Pi
and from direct monitoring of NTP by 31P MRS vs. time in each animal could be explained
by a profound decrease in mitochondrial metabolism following LND administration. This
could have been the result of a direct effect of LND on electron transport as Floridi and
Lehninger argued on the basis of polarographic data on isolated mitochondria from Ehrlich
Ascites cells (41), or it could have been the result of inhibition of pyruvate transport into
mitochondria resulting in substrate deprivation for the TCA cycle. The latter explanation is
simpler and appears more plausible in view of the demonstration by Spencer and Lehninger
(35) that another MCT inhibitor, CHC, blocks transport of both lactate out of the plasma
membrane and transport of pyruvate through the mitochondrial membrane.
Overall, our data are fully consistent with the conclusion of Ben-Horin et al. (39) that LND
is an inhibitor of the MCT in tumors, thereby impeding export of lactate into the
extracellular milieu and accounting for the intracellular acidification induced by LND. If this
agent also impedes the transport of pyruvate into mitochondria depriving these organelles of
the substrate required for oxidative phosphorylation, the de-energization of the tumor
induced by LND would be explained as well. Previously we delivered LND on DB-1
melanomas (15), we delivered the drug i.p. in DMSO solution under hyperglycemic
conditions (26 mM blood glucose), maintained by infusion of exogenous glucose. This led
to a high level of tumor acidification and de-energization, but the animals used in this
preliminary study died. This mortality was completely avoided by eliminating the glucose
infusion and by dissolving LND in tris/glycine pH 8.3 buffer before i.p. injection as
suggested by Ben-Yoseph et al. (40). This method produced a stable and reproducible
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intracellular acidification of the tumor at pHi = 6.33 ± 0.10 over a 3 hr period (Fig. 2)
comparable to what had been reported in the previous study by Zhou et al. (15)
Blood tests of mice treated with LND do not indicate any significant renal, bone marrow or
hepatic toxicity. Myalgia, and hence muscle toxicity, has been reported in the clinic (42–44).
No effect of LND on pHi, pHe or ATP/Pi of muscle was observed in this study (Fig. 2), but
it must be remembered that the animals were anesthetized, and hence there was no muscle
activity. White muscle fibers are expected to exhibit high levels of glycolytic metabolism
during exercise.
We have observed about 30% decrease in the ATP/Pi ratio in DB-1 melanoma xenografts
subjected to hyperglycemia and treated with MIBG and CHC (14, 15), and in the current
study LND produced a small but transient decrease in liver pHi by 0.2 units and a decrease
in ATP/Pi of the liver at 20 min and 40 min, respectively, post-LND administration (Fig. 2).
Thus, some liver toxicity may accompany treatment with LND. However, these side effects
have not precluded the use of LND in the clinic on over 3500 cancer patients since the early
1980s (H. Seleck, personal communication) and should not prevent the future use in cancer
therapy.
As noted above, the activity of platinum compounds and N-mustard alkylating agents (10–
13, 16–19) increases with increasing acidification of tumors. In the case of N-mustards, this
appears to be due to three effects: 1) increased concentrations of the active intermediate
cyclic aziridinium ion intermediate, 2) decreased concentrations of competing nucleophiles
such as hydroxide and glutathione, whose production is diminished by decreased activity of
gluthathione-S-transferase under acidic conditions, and 3) decreased DNA repair due to acid
inhibition of O6-alkyltransferase (17, 19). This is probably largely because acid shifts the
equilibrium between the various forms of these agents towards more active forms. In the
case of N-mustards, the active species is the cyclic aziridinium ion. In cells, the reactivity of
these agents will also be affected by considerations of transport into the cell and eventually
into the nucleus, where DNA alkylation occurs. Sequestration of these agents in lysosomes
or other organelles may adversely affect their antineoplastic activity. All these
considerations apply to the potential activity of these alkylating agents against melanomas
and other tumor cells.
Under neutral conditions such as were utilized in ex vivo screening of various alkylating
agents, all of the agents should have been able to enter the DB-1 tumor cells. This study
indicates that the rank order of reactivity against DB-1 cells of these agents was LPAM >
cisplatin > bendamustine > chlorambucil > LND. This makes LPAM an ideal candidate for
treatment of DB-1 melanoma xenografts as shown by our previous success with LPAM
following acidification in the treatment of melanoma implanted in the hind limb of a rat
(16).
In view of this, LPAM seemed to be a good candidate for enhanced activity following DB-1
acidification by LND treatment. LPAM had substantial activity against DB-1 melanoma
when administered alone, and this activity was substantially enhanced following the addition
of LND, yielding approximately one log order of tumor cell-kill with one treatment. In
addition, the animals fully recovered their body weight within about 14 days following
treatment with LPAM + LND. Overall, LND + LPAM killed about 90% of the tumor cells.
If we waited for about 12 days (i.e., two doubling times) to administer a second dose, the
tumor volume should grow back to 40% of its initial volume, and then be diminished again
by 90% to 94% of the initial volume since the same dose of drug should produce the same
fractional cell kill (45). These results clearly points to a net gain in treatment of DB-1
melanoma with multiple cycles of LPAM + LND. There may be additional beneficial effects
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of prolonged and multiple intervals of intracellular acidification associated with inhibition of
multidrug resistance (MDR) (46, 47).
LPAM has been used extensively in the clinic in the treatment of multiple myeloma and is
known to have considerable bone-marrow toxicity (48). Patients usually require bone
marrow transplantation, which has considerable risk of mortality. Other N-mustards such as
bendamustine exhibit much lower toxicity (49). This drug and perhaps also
cyclophosphamide or other N-mustards may exhibit a better overall therapeutic ratio than
LPAM. We plan to explore this possibility in future studies.
In summary, we have achieved our key objective of developing a simple and reproducible
procedure for acute intracellular acidification of DB-1 melanomas using the single agent
LND, which has been used in clinical treatment of cancer patients for over 30 years.
Specifically we have demonstrated that LND-mediates acidification and de-energization
selectively in the tumor over a 3 hr period with no effect on muscle or brain and only a much
smaller and transient effect on the liver. We demonstrated accumulation of lactate in the
tumor by lactate imaging in vivo together with measurements of pHi and pHe demonstrating
that the acidification was predominantly in the tumor. Increase of the tumor cell membrane
pH gradient provides further support for the MCT inhibitor mechanism of LND activity and
also suggests that weak bases like doxorubicin should accumulate in melanoma cells after
LND administration. We have demonstrated that the effects of 100 mg/kg, i.p. LND without
exogenous glucose do not produce mortality and that administration of LND in tris/glycine
pH 8.3 buffer avoids mortality even under hyperglycemic conditions. Finally, we showed
that LPAM in combination with LND is a good candidate for systemic therapy of melanoma
and perhaps other malignancies such as multiple myeloma that are routinely treated with
LPAM. Our study provides further support for MCT inhibition being the primary
mechanism by which LND modifies intracellular pH and bioenergetics of tumors. Other
MCT inhibitors are currently under development by AstraZeneca, Inc. and may exhibit
similar properties to LND in modifying tumor pHi and bioenergetics. These agents may,
therefore, play an important role in modifying the tumor microenvironment to make cancer
more susceptible to certain classes of chemotherapeutic agents and to hyperthermia.
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Abbreviations
LND Lonidamine
LPAM Melphalan
MRS Magnetic Resonance Spectroscopy
MCT Monocarboxylate Transporter
pHi Intracellular pH
pHe Extracellular pH
3-APP 3-Aminopropylphosphonate
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PME Phosphomonoester
Pi Inorganic Phosphate
PDE Phosphodiester
MIBG Meta-iodobenzylguanidine
i.p intraperitoneal
s.c. Subcutaneous
CHC α-cyano-4-hydroxycinnamic acid
TCA tricarboxylic acid
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Figure 1.
In vivo localized (Image Selected In vivo Spectroscopy - ISIS) 31Phosphorus magnetic
resonance spectroscopy (31P MRS) spectra of human melanoma xenograft grown
subcutaneously in nude mice (A) pre- and (B) 180 min post administration of LND (100 mg/
kg, i.p.). Resonance assignments are as follows, 3-APP (3-aminopropylphosphonate); PME
(phosphomonoesters); Pi (inorganic phosphate); PDE (phosphodiesters); γ-NTP (γ-
nucleoside-triphosphate), α-NTP (α-nucleoside-triphosphate), β-NTP (β-nucleoside-
triphosphate). Decrease in β-NTP levels and the corresponding increase in Pi following
LND administration (Spectrum B) indicating impaired energy metabolism.
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Figure 2.
(A). The intracellular pH (pHi) profile as a function of time of human melanoma xenografts
(n = 15) and normal tissues [skeletal muscle (n = 6), liver (n = 6), and brain (n = 3)] in
response to LND (100 mg/kg; i.p.) administration at time zero. (B). The extracellular pH
(pHe) profile as a function of time of human melanoma xenografts (n = 4) and normal
tissues [skeletal muscle (n = 3) and liver (n = 3),] in response to LND (100 mg/kg; i.p.)
administration at time zero. (C). Change in tumor lactate as a function of time after
administration of LND (100 mg/kg). Area under the curve was compared to baseline at each
time points and was normalized to baseline levels. (D). The changes of NTP/Pi (ratio of
peak area) relative to baseline as a function of time of human melanoma xenografts (n=15)
and normal tissues [skeletal muscle (n = 6), liver (n = 6), and brain (n = 3)] in response to
LND (100 mg/kg; i.p.) administration at time zero. The values are presented as mean ±
S.E.M. When not displayed, S.E.M. values were smaller than the symbol size.
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Figure 3.
Spectra show the effect of LND (100 mg/kg) on tumor lactate production. The lactate peak
is at 1.3 ppm. Spectra were obtained before any treatment (0 min) and after 60, 120 min and
180 min following LND administration.
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Figure 4.
Growth delay experiments performed on DB-1 human melanoma xenografts in nude mice
treated with 7.5 mg/kg LPAM. Mice were treated on Day 0 as follows: Control (sham i.p.
tris/glycine buffer + sham i.v. PBS), LND, LPAM, LND + LPAM. Values shown are means
± SEM for n = 4 animals, Control and LND groups; n = 3 animals, LPAM and LND +
LPAM groups. When not shown, error bars are less than symbol size.
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